Question · asked by 1 review
Nebulised magnesium sulfate + standard care vs placebo + standard care: Proportion of people with serious adverse events
- Population
- acute exacerbations of chronic obstructive pulmonary disease
- Intervention
- Nebulised magnesium sulfate + standard care
- Comparison
- placebo + standard care
- Outcome
- Proportion of people with serious adverse events
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Nebulised magnesium sulfate + standard care vs placebo + standard care Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease The review found no eligible studies for this question. Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.